Plus   Neg

After Hours Market: Marinus Pharma, Novus Therapeutics And NextEra Energy Gain; Nikola Slips

Marinus Pharmaceuticals, Inc. (MRNS) - Shares of the drug company surged nearly 70% in after-hours trading on Monday. Marinus announced that its Ganaxolone achieved primary endpoint in late stage trial for CDKL5 deficiency disorder, a rare form of genetic epilepsy. The company plans to submit New Drug Application by mid-2021 with commercial launch targeted for first half of 2022.

Novus Therapeutics, Inc. (NVUS) - The nano-cap company's stock soared over 140% in after-hours period after the company announced it has completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.

NextEra Energy, Inc. (NEE) - Shares of the company jumped nearly 6% after the bell on Monday after the company lifted its financial outlook and announced a 4:1 stock split. For 2021, NextEra Energy increased its financial expectations by $0.20 and now expects adjusted earnings of $9.60 to $10.15 per share. Analysts polled by Thomson Reuters currently estimate earnings of $9.88 per share. For 2022 and 2023, NextEra Energy expects to grow 6% to 8%

Nikola Corp. (NKLA) - The electric car company's shares slipped 8% in extended trading on Monday after a Bloomberg report that the Securities and Exchange Commission will examine the company after a short seller report alleged that Nikola deceived investors about its business prospects. Nikola said that the report had "dozens" of inaccuracies and that it had contacted the SEC.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT